Kadmon Corporation

From WikiMD's WELLNESSPEDIA

Kadmon Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company was founded in 2010 by Sam Waksal, who previously founded ImClone Systems, a biopharmaceutical company that was sold to Eli Lilly and Company in 2008.

History[edit]

Kadmon Corporation was established in 2010 by Sam Waksal. The company's initial focus was on the development of small molecules and biologics in the areas of oncology, immunology, and infectious disease. In 2016, Kadmon Corporation went public, trading on the New York Stock Exchange under the ticker symbol "KDMN".

Research and Development[edit]

Kadmon Corporation's research and development efforts are primarily focused on the areas of oncology, immunology, and infectious disease. The company's lead product candidate, KD025, is a ROCK2 inhibitor that is currently in Phase 2 clinical trials for the treatment of chronic graft-versus-host disease (cGVHD) and systemic sclerosis. Other product candidates in Kadmon's pipeline include KD033, an anti-PD-L1/IL-15 fusion protein, and KD045, a ROCK inhibitor for the treatment of fibrotic diseases.

Financials[edit]

As a publicly traded company, Kadmon Corporation's financial performance is reported on a quarterly and annual basis. The company's revenue primarily comes from product sales, licensing agreements, and research collaborations.

Criticism and Controversy[edit]

Kadmon Corporation has faced criticism and controversy, particularly in relation to its founder, Sam Waksal. Waksal has a history of legal troubles, including a conviction for insider trading while at ImClone Systems. Despite these controversies, Kadmon Corporation continues to operate and pursue its research and development goals.

See Also[edit]

References[edit]


This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Kadmon_Corporation&oldid=6616179"